BAG3 Positivity as Prognostic Marker in Head and Neck Squamous Cell Carcinoma
Authors:
- Pietro De LucaPLPietro De Luca
- Francesco Antonio SalzanoFrancesco Antonio Salzano
- Angelo CamaioniACAngelo Camaioni
- Leopoldo CostarelliLCLeopoldo Costarelli
- Raul PelliniRPRaul Pellini
- Gerardo PetruzziGPGerardo Petruzzi
- Renato CovelloRCRenato Covello
- Luigi VittoriLVLuigi Vittori
- Filippo RicciardielloFRFilippo Ricciardiello
- Giuseppe RicciardielloGRGiuseppe Ricciardiello
- Alessandro IacobelliAIAlessandro Iacobelli
- Anna Lisa CammarotaACAnna Lisa Cammarota
Open Access
Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) exhibit considerable heterogeneity, complicating the prediction of disease progression and treatment response. Consequently, researchers are actively investigating reliable biomarkers to forecast disease trajectories and inform therapeutic decisions. This study examines the role of BAG3, a protein involved in cell survival and stress response, as a potential predictive marker in HNSCC. The objective is to analyze BAG3 expression across various HNSCC types and correlate it with disease-free survival (DFS), aiming to elucidate the influence of BAG3 positivity on cancer progression. Methods: A multi-institutional retrospective study was conducted by analyzing BAG3 expression by immunohistochemistry in 104 tissue samples from patients with head and neck squamous cell carcinoma (HNSCC). The data were then correlated with DFS to assess the impact of BAG3 positivity on prognosis. Results: Immunohistochemical analysis of primary tumor samples collected from therapy-naive patients showed that BAG3 positivity was widespread across different head and neck cancer sites, with no significant correlation to sex, smoking status, HPV infection, tumor location, grade, or TNM parameters. However, BAG3 high positive patients had shorter DFS (median 23.2 months) compared to BAG3-negative patients (median 31.3 months). Cox analysis revealed that BAG3 high expression by IHC was associated with a more than 3-fold increased risk of disease recurrence. Conclusions: This study is the first to explore BAG3 as a biomarker for HNSCC recurrence. While preliminary findings suggest a link between BAG3 positivity and increased recurrence risk, further research is needed to validate these results. Prospective studies could help establish BAG3’s prognostic value and potentially lead to more personalized treatment approaches for HNSCC.Keywords
This publication has 47 references indexed in Scilit:
- The Burden of Recurrent Head and Neck Squamous Cell Carcinoma Across the United Kingdom: Results From a National Snapshot StudyHead & Neck, 2024
- Developments and future prospects of personalized medicine in head and neck squamous cell carcinoma diagnoses and treatmentsCancer Reports, 2024
- A comprehensive prognostic score for head and neck squamous cancer driver genes and phenotype traitsDiscover Oncology, 2023
- Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocolsCancer, 2023
- Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 UpdateDrugs, 2023
- Tumor Histological Grade and Immunotherapy Response in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaJAMA Otolaryngology–Head & Neck Surgery, 2022
- BAG3 induces α‐SMA expression in human fibroblasts and its over‐expression correlates with poorer survival in fibrotic cancer patientsJournal of Cellular Biochemistry, 2021
- Variations in the association of grade with survival across the head and neck cancer landscapeHead & Neck, 2020
- High expression of BAG3 predicts a poor prognosis in human medulloblastomaTumor Biology, 2016
- BAG3 Protein Is Overexpressed in Human Glioblastoma and Is a Potential Target for TherapyThe American Journal of Pathology, 2011